= Zometa zoledronic acid (a bisphosphonate) prevents bone loss in women with early breast cancer undergoing chemotherapy, according to randomized placebo-controlled phase III study. Article posted August 23, 2008
August 23, 2008: Journal of Clinical Oncology, 10.1200/JCO.2008.16.4707
Yet another randomized placebo-controlled phase III study shows that zoledronic acid Zometa = bone loss in women with breast cancer receiving chemotherapy. Read the full study results in this report but it is scandalous that our view of Dutch women with breast cancer still remember when Zometa treatment for breast cancer. There are so many Phase III studies that prove even more cost effective and Zometa is that our opinion is worth as your doctor would not prescribe you can report to the Inspectorate of Health. See full study report about this new study
Zoledronic Acid Prevents Bone Loss in Women Under Going premenopausal Adjuvant Chemotherapy for Early-Stage Breast Cancer
From the Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
* To Whom Correspondence Should Be Addressed. E-mail: dlh23@columbia.edu
Purpose: Adjuvant chemotherapy for breast cancer (BC) May Be associated with Increased Decreased rates of bone loss and bone mineral density (BMD) and May lead to premature osteoporosis and Increased fracture risk. We Examined whethere zoledronic acid (ZA) Prevents bone loss in premenopausal women receiving chemotherapy for early stage BC.
Patients and Methods: This Study is a randomized, double-blind, multicenter, phase III Trial Comparing ZA (4 mg intravenously everytime 3 months) versus placebo for 1 year. Premenopausal women went under serial BMD Initiating measurements before chemotherapy and at 6 and 12 months. The primary outcome was percent change in lumbar spine (LS) BMD at 6 months. Secondary outcomes Were percentage change AT ANY BMD site and markers of bone turnover at 12 months. Linear mixed model analysis for repeated measurements was Performed.
Results: Of 101 Women Who Were Randomly Assigned and completed baseline evaluation, 96 completed the 6-month evaluation, and 85 completed the 12-month evaluation. Baseline Characteristics Were comparable Between the groups. Mean age was 42 years. Placebo was associated with significant decline in LS BMD at Both 6 (2.4%) and 12 (4.1%) months. Similarly, total hip BMD Declined by 0.8% at 6 months and 2.6% at 12 months. In contrast, BMD remained stable in SA patients (P <.0001 compared with placebo).
Conclusion: premenopausal women receiving chemotherapy for BC sustained significant bone loss at the LS and hip, whereas BMD remained stable in women who Received ZA. Administration of ZA consistently the first year or chemotherapy is an effective and well-tolerated strategy for Preventing bone loss.
